Neurogene (NGNE) Income from Continuing Operations (2013 - 2026)

Neurogene (NGNE) has 14 years of Income from Continuing Operations data on file, last reported at 38288000.0 in Q1 2026.

• Quarterly Income from Continuing Operations fell 63.53% year-over-year to 38288000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 111982000.0 (up 2.28% YoY) and the FY2025 annual result came in at 231557000.0, down 22.45% from the prior year.
• Income from Continuing Operations fell to 38288000.0 in Q1 2026, from 25082000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 11868000.0 in Q2 2023 to a low of 49839000.0 in Q4 2022.
• A 5-year average of 24869647.06 and a median of 23413000.0 in 2025 frame the typical range for Income from Continuing Operations.
• Annual changes were most pronounced in 2022 — Income from Continuing Operations soared 72.34% — and 2024, when it plunged 296.86%.
• Tracing NGNE's Income from Continuing Operations over 5 years: stood at 49839000.0 in 2022, then soared by 71.97% to 13971000.0 in 2023, then slumped by 37.74% to 19244000.0 in 2024, then sank by 30.34% to 25082000.0 in 2025, then sank by 52.65% to 38288000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 38288000.0 (Q1 2026), 25082000.0 (Q4 2025), and 23959000.0 (Q3 2025), per Business Quant data.